These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 32162812)

  • 1. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
    van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
    J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
    Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer.
    Nakamura Y; Yoshino T
    Oncologist; 2018 Nov; 23(11):1310-1318. PubMed ID: 29700206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Circulating Tumor DNA Profiling in Metastatic Colorectal Cancer During Anti-EGFR Therapy.
    Yang W; Zou J; Li Y; Liu R; Yan Z; Chen S; Zhao X; Guo W; Huang M; Li W; Zhu X; Chen Z
    Front Oncol; 2022; 12():830816. PubMed ID: 35280779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS and NRAS mutational analysis in plasma ctDNA from patients with metastatic colorectal cancer by real-time PCR and digital PCR.
    Pinheiro M; Peixoto A; Rocha P; Veiga I; Pinto C; Santos C; Pinto P; Guerra J; Escudeiro C; Barbosa A; Silva J; Teixeira MR
    Int J Colorectal Dis; 2022 Apr; 37(4):895-905. PubMed ID: 35303157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Genomic Analysis of Patients With Non-Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan.
    Wang HY; Ho CC; Lin YT; Liao WY; Chen CY; Shih JY; Yu CJ
    JCO Precis Oncol; 2024 Jan; 8():e2300314. PubMed ID: 38190582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer.
    Cao W; Xu Y; Chang L; Gong Y; Li L; Mo X; Zhang X; Lin G; Zhou J; Liu D; Yi Y; Dai P; Zhu C; Liu T; Chu Y; Guan Y; Chen Y; Wang J; Xia X; Yang L; Yi X; Cheng Y
    Mol Cancer Ther; 2019 Jun; 18(6):1158-1167. PubMed ID: 31015309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance.
    Barata PC; Koshkin VS; Funchain P; Sohal D; Pritchard A; Klek S; Adamowicz T; Gopalakrishnan D; Garcia J; Rini B; Grivas P
    Ann Oncol; 2017 Oct; 28(10):2458-2463. PubMed ID: 28945843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma ctDNA enhances the tissue-based detection of oncodriver mutations in colorectal cancer.
    Wang W; Huang Y; Kong J; Lu L; Liao Q; Zhu J; Wang T; Yan L; Dai M; Chen Z; You J
    Clin Transl Oncol; 2024 Aug; 26(8):1976-1987. PubMed ID: 38777950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
    Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
    Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
    Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
    Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of genomic alterations between tumor tissue and circulating tumor DNA by next-generation sequencing.
    Chang YS; Fang HY; Hung YC; Ke TW; Chang CM; Liu TY; Chen YC; Chao DS; Huang HY; Chang JG
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2167-2175. PubMed ID: 30203147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases.
    Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM
    Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.